BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Walters MDS, Matthei IU, Kay R, Dillon MJ, Barratt TM. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1989;3:130-4. [DOI: 10.1007/bf00852893] [Cited by in Crossref: 105] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Taylor CM, Monnens LA. Advances in haemolytic uraemic syndrome. Arch Dis Child 1998;78:190-3. [PMID: 9579168 DOI: 10.1136/adc.78.2.190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
2 Milford DV, Taylor CM. New insights into the haemolytic uraemic syndromes. Arch Dis Child 1990;65:713-5. [PMID: 2201260 DOI: 10.1136/adc.65.7.713] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
3 McLaine PN. Hemolytic uremic syndrome: Events of the past decade. Paediatr Child Health 2002;7:533-7. [PMID: 20046465 DOI: 10.1093/pch/7.8.533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Ramos MV, Mejias MP, Sabbione F, Fernandez-Brando RJ, Santiago AP, Amaral MM, Exeni R, Trevani AS, Palermo MS. Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome. J Innate Immun 2016;8:400-11. [PMID: 27230920 DOI: 10.1159/000445770] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
5 Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. Early erythropoietin in post-diarrheal hemolytic uremic syndrome: a case-control study. Pediatr Nephrol 2015;30:339-44. [PMID: 25138373 DOI: 10.1007/s00467-014-2911-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2013;28:919-25. [PMID: 23386110 DOI: 10.1007/s00467-013-2414-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
7 Holle JU, Williams JM, Harper L, Savage CO, Taylor CM. Effect of verocytotoxins (Shiga-like toxins) on human neutrophils in vitro. Pediatr Nephrol 2005;20:1237-44. [PMID: 15947986 DOI: 10.1007/s00467-005-1945-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
8 Taylor CM, Milford DV, White RH. A plea for standardized terminology within the haemolytic uraemic syndromes. Pediatr Nephrol 1991;5:97. [PMID: 2025550 DOI: 10.1007/BF00852859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Gómez SA, Fernández GC, Camerano G, Dran G, Rosa FA, Barrionuevo P, Isturiz MA, Palermo MS. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome. Clin Exp Immunol 2005;139:65-73. [PMID: 15606615 DOI: 10.1111/j.1365-2249.2005.02659.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
10 Brigotti M. The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety? Toxins (Basel) 2012;4:157-90. [PMID: 22741061 DOI: 10.3390/toxins4030157] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
11 Fitzpatrick MM, Dillon MJ. Current views on aetiology and management of haemolytic uraemic syndrome. Postgrad Med J 1991;67:707-9. [PMID: 1754520 DOI: 10.1136/pgmj.67.790.707] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child 1990;65:716-21. [PMID: 2201261 DOI: 10.1136/adc.65.7.716] [Cited by in Crossref: 115] [Cited by in F6Publishing: 108] [Article Influence: 3.6] [Reference Citation Analysis]
13 Ağbaş A, Göknar N, Akıncı N, Yıldırım ZY, Taşdemir M, Benzer M, Gökçe İ, Candan C, Küçük N, Uzuner S, Özçelik G, Demirkol D, Sever L, Çalışkan S. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatr Nephrol 2018;33:2371-81. [PMID: 30159625 DOI: 10.1007/s00467-018-4033-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
14 Trojnar E, Józsi M, Szabó Z, Réti M, Farkas P, Kelen K, Reusz GS, Szabó AJ, Garam N, Mikes B, Sinkovits G, Mező B, Csuka D, Prohászka Z. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Front Immunol 2019;10:240. [PMID: 30858847 DOI: 10.3389/fimmu.2019.00240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Elzouki AY, Mirza K, Mahmood A, Al-Sowailem AM. Hemolytic uremic syndrome - clinical aspects and outcome of an outbreak: Report of 28 cases. Ann Saudi Med 1995;15:113-6. [PMID: 17587918 DOI: 10.5144/0256-4947.1995.113] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Brigotti M, Carnicelli D, Ravanelli E, Vara AG, Martinelli C, Alfieri RR, Petronini PG, Sestili P. Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin. Infect Immun 2007;75:2201-7. [PMID: 17296757 DOI: 10.1128/IAI.01707-06] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
17 Inward CD, Varagunam M, Adu D, Milford DV, Taylor CM. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection. Arch Dis Child 1997;77:145-7. [PMID: 9301354 DOI: 10.1136/adc.77.2.145] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 2.2] [Reference Citation Analysis]
18 Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001;69:6148-55. [PMID: 11553554 DOI: 10.1128/IAI.69.10.6148-6155.2001] [Cited by in Crossref: 115] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
19 Jandhyala DM, Rogers TJ, Kane A, Paton AW, Paton JC, Thorpe CM. Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation. Infect Immun 2010;78:2984-94. [PMID: 20439475 DOI: 10.1128/IAI.00383-10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
20 Robson WL. Haemolytic uraemic syndrome. Paediatr Drugs 2000;2:243-52. [PMID: 10946413 DOI: 10.2165/00128072-200002040-00001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Obata F, Obrig T. Role of Shiga/Vero toxins in pathogenesis. Microbiol Spectr 2014;2. [PMID: 25530918 DOI: 10.1128/microbiolspec.EHEC-0005-2013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) 2012;4:1261-87. [PMID: 23202315 DOI: 10.3390/toxins4111261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
23 Fernandez GC, Lopez MF, Gomez SA, Ramos MV, Bentancor LV, Fernandez-Brando RJ, Landoni VI, Dran GI, Meiss R, Isturiz MA, Palermo MS. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Clin Exp Immunol 2006;146:76-84. [PMID: 16968401 DOI: 10.1111/j.1365-2249.2006.03155.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
24 Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998;11:450-79. [PMID: 9665978 DOI: 10.1128/CMR.11.3.450] [Cited by in Crossref: 936] [Cited by in F6Publishing: 357] [Article Influence: 39.0] [Reference Citation Analysis]
25 Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Long term renal outcome of childhood haemolytic uraemic syndrome. BMJ 1991;303:489-92. [PMID: 1912857 DOI: 10.1136/bmj.303.6801.489] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
26 Biernbaum EN, Kudva IT. AB5 Enterotoxin-Mediated Pathogenesis: Perspectives Gleaned from Shiga Toxins. Toxins (Basel) 2022;14:62. [PMID: 35051039 DOI: 10.3390/toxins14010062] [Reference Citation Analysis]
27 Roche JK, Keepers TR, Gross LK, Seaner RM, Obrig TG. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation. Am J Pathol 2007;170:526-37. [PMID: 17255321 DOI: 10.2353/ajpath.2007.060366] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
28 Tsai M, Kita A, Leach J, Rounsevell R, Huang JN, Moake J, Ware RE, Fletcher DA, Lam WA. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest 2012;122:408-18. [PMID: 22156199 DOI: 10.1172/JCI58753] [Cited by in Crossref: 180] [Cited by in F6Publishing: 109] [Article Influence: 16.4] [Reference Citation Analysis]
29 Chiyoda S, Takeda T, Aoki Y. Shiga toxin 2 induces macrophage-granulocyte colonies from human bone marrow and cord blood stem cells. Infect Immun 2002;70:5316-8. [PMID: 12183591 DOI: 10.1128/IAI.70.9.5316-5318.2002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Azim T, Sarker MS, Hamadani J, Khanum N, Halder RC, Salam MA, Albert MJ. Alterations in lymphocyte phenotype and function in children with shigellosis who develop complications. Clin Diagn Lab Immunol 1996;3:191-6. [PMID: 8991634 DOI: 10.1128/cdli.3.2.191-196.1996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Fitzpatrick MM, Shah V, Filler G, Dillon MJ, Barratt TM. Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma. Pediatr Nephrol 1992;6:50-3. [PMID: 1536740 DOI: 10.1007/BF00856833] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
32 Brigotti M, Caprioli A, Tozzi AE, Tazzari PL, Ricci F, Conte R, Carnicelli D, Procaccino MA, Minelli F, Ferretti AV, Paglialonga F, Edefonti A, Rizzoni G. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol 2006;44:313-7. [PMID: 16455876 DOI: 10.1128/JCM.44.2.313-317.2006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
33 Pirschel W, Mestekemper AN, Wissuwa B, Krieg N, Kröller S, Daniel C, Gunzer F, Tolosano E, Bauer M, Amann K, Heinemann SH, Coldewey SM. Divergent roles of haptoglobin and hemopexin deficiency for disease progression of Shiga-toxin-induced hemolytic-uremic syndrome in mice. Kidney Int 2022:S0085-2538(22)00016-3. [PMID: 35031328 DOI: 10.1016/j.kint.2021.12.024] [Reference Citation Analysis]
34 Vallés PG, Melechuck S, González A, Manucha W, Bocanegra V, Vallés R. Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome. Pediatr Nephrol 2012;27:407-15. [PMID: 21969092 DOI: 10.1007/s00467-011-2014-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
35 Beattie TJ. Recent developments in the pathogenesis of hemolytic uremic syndrome. Ren Fail 1990;12:3-7. [PMID: 2236721 DOI: 10.3109/08860229009066958] [Reference Citation Analysis]